<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Genetics Delivery Team</style></author><author><style face="normal" font="default" size="100%">Boutin, Thibaud</style></author><author><style face="normal" font="default" size="100%">Bretherick, Andrew D.</style></author><author><style face="normal" font="default" size="100%">Dibble, Joshua J.</style></author><author><style face="normal" font="default" size="100%">Ewaoluwagbemiga, Esther</style></author><author><style face="normal" font="default" size="100%">Northwood, Emma</style></author><author><style face="normal" font="default" size="100%">Samms, Gemma L.</style></author><author><style face="normal" font="default" size="100%">Vitart, Veronique</style></author><author><style face="normal" font="default" size="100%">Project and Cohort Delivery Team</style></author><author><style face="normal" font="default" size="100%">Almelid, Øyvind</style></author><author><style face="normal" font="default" size="100%">Baker, Tom</style></author><author><style face="normal" font="default" size="100%">Clyde, Malgorzata</style></author><author><style face="normal" font="default" size="100%">Connolly, Anne</style></author><author><style face="normal" font="default" size="100%">Garcia, Diana</style></author><author><style face="normal" font="default" size="100%">Kerr, Shona M.</style></author><author><style face="normal" font="default" size="100%">Tripp, Claire</style></author><author><style face="normal" font="default" size="100%">Wolfe, Jareth C.</style></author><author><style face="normal" font="default" size="100%">Patient and Public Involvement</style></author><author><style face="normal" font="default" size="100%">Goold, Jackie</style></author><author><style face="normal" font="default" size="100%">Hoyes, Gemma</style></author><author><style face="normal" font="default" size="100%">Leary, Sian</style></author><author><style face="normal" font="default" size="100%">McGrath, Simon J.</style></author><author><style face="normal" font="default" size="100%">Milton, Julie</style></author><author><style face="normal" font="default" size="100%">Redshaw, Anna</style></author><author><style face="normal" font="default" size="100%">Wilson, Jim M.</style></author><author><style face="normal" font="default" size="100%">Marketing and Communications Team</style></author><author><style face="normal" font="default" size="100%">Baxter, Helen</style></author><author><style face="normal" font="default" size="100%">Boobyer, Danielle</style></author><author><style face="normal" font="default" size="100%">Dransfield, Claire</style></author><author><style face="normal" font="default" size="100%">Lamirel, Daphne</style></author><author><style face="normal" font="default" size="100%">Lewis, Isabel</style></author><author><style face="normal" font="default" size="100%">Muirhead, Nina</style></author><author><style face="normal" font="default" size="100%">Ponting, Ella</style></author><author><style face="normal" font="default" size="100%">Shepherd, Charles</style></author><author><style face="normal" font="default" size="100%">Turner, Alice</style></author><author><style face="normal" font="default" size="100%">University of Edinburgh Team</style></author><author><style face="normal" font="default" size="100%">Baby, Sumy V.</style></author><author><style face="normal" font="default" size="100%">Beentjes, Sjoerd</style></author><author><style face="normal" font="default" size="100%">Ireland, John</style></author><author><style face="normal" font="default" size="100%">Khamseh, Ava</style></author><author><style face="normal" font="default" size="100%">McDowall, Ewan</style></author><author><style face="normal" font="default" size="100%">Perry, David</style></author><author><style face="normal" font="default" size="100%">Slaughter, Joshua</style></author><author><style face="normal" font="default" size="100%">Genetic Epidemiology of ME/CFS Consortium</style></author><author><style face="normal" font="default" size="100%">Abner, Erik</style></author><author><style face="normal" font="default" size="100%">Boer, Cindy G.</style></author><author><style face="normal" font="default" size="100%">Estonian Biobank Research Team</style></author><author><style face="normal" font="default" size="100%">Finer, Sarah</style></author><author><style face="normal" font="default" size="100%">Genes &amp; Health Research Team</style></author><author><style face="normal" font="default" size="100%">Haapaniemi, Hele</style></author><author><style face="normal" font="default" size="100%">Ollila, Hanna M.</style></author><author><style face="normal" font="default" size="100%">Pollack, Beth</style></author><author><style face="normal" font="default" size="100%">Rosmalen, Judith</style></author><author><style face="normal" font="default" size="100%">Romppanen, Erika</style></author><author><style face="normal" font="default" size="100%">Saafi, Sirine</style></author><author><style face="normal" font="default" size="100%">Saxena, Richa</style></author><author><style face="normal" font="default" size="100%">Sinnott-Armstrong, Nasa</style></author><author><style face="normal" font="default" size="100%">Tervi, Anniina</style></author><author><style face="normal" font="default" size="100%">Urpa, Lea</style></author><author><style face="normal" font="default" size="100%">Valliere, Jesse</style></author><author><style face="normal" font="default" size="100%">van Heel, David A.</style></author><author><style face="normal" font="default" size="100%">Management Team</style></author><author><style face="normal" font="default" size="100%">Chowdhury, Sonya</style></author><author><style face="normal" font="default" size="100%">Devereux-Cooke, Andy</style></author><author><style face="normal" font="default" size="100%">Ponting, Chris P.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">medRxiv</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-01-01 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">2025.08.06.25333109</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.1101/2025.08.06.25333109</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is a common, poorly understood disease that has no effective treatments, and has long been underserved by scientific research and national health systems. It is a sex-biased disease towards females that is often triggered by an infection, and its hallmark symptom is post-exertional malaise. People with ME/CFS often report their symptoms being disbelieved. The biological mechanisms causing ME/CFS remain unclear. We recruited 21,620 ME/CFS cases and performed genome-wide association studies (GWAS) for up to 15,579 cases and 259,909 population controls with European genetic ancestry. In these GWAS, we discovered eight loci that are significantly associated with ME/CFS, including three near BTN2A2, OLFM4, and RABGAP1L genes that act in the response to viral or bacterial infection. Four of the eight loci (RABGAP1L, FBXL4, OLFM4, CA10) were associated at p &lt; 0.05 with cases ascertained using post-exertional malaise and fatigue in the UK Biobank and the Netherlands biobank Lifelines. We found no evidence of sex-bias among discovered associations, and replicated in males two genetic signals (ARFGEF2, CA10) discovered in females. The ME/CFS association near CA10 colocalises with a known association to multisite chronic pain. We found no evidence that the eight ME/CFS genetic signals share common causal genetic variants with depression or anxiety. Our findings suggest that both immunological and neurological processes are involved in the genetic risk of ME/CFS.LAY SUMMARY Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is a common, disabling illness. It affects more females than males, and in most cases, starts after an infection. Little is known about the biological mechanisms that cause ME/CFS, despite many attempts to uncover them, and it has no effective treatments. To understand ME/CFS better, our study, DecodeME, compared the DNA of 15,579 people with ME/CFS with the DNA of 259,909 people without ME/CFS, all of European descent. DNA is a molecule that makes up our genes. Our genes make many different molecules called proteins, each of which does very specific things in the body. Finding variations in genes that differ between people with or without a disease can therefore point to what causes it. We found that people with ME/CFS are more likely to carry certain DNA differences in eight regions of their genome, and so these variants tell us about possible biological causes of ME/CFS. However, as these differences are also often found in people without ME/CFS they cannot cleanly separate who is at risk and who is not, and therefore do not provide a definitive test. Most of these regions contain several genes. Our methods did not allow us to conclusively locate the ones most relevant to ME/CFS in each region, but public data allowed us to pick out the most likely ones. Three of the most likely genes produce proteins that respond to an infection. Another likely gene is related to chronic pain. None are related to depression or anxiety. We found nothing to explain why more females than males get ME/CFS. Overall, DecodeME shows that ME/CFS is partly caused by genes related to the immune and nervous systems.Competing Interest StatementADC was until April 2025 a committee member of the Science for ME online support discussion forum. CPP has had PhD studentships funded by Action for ME, the Chief Scientist Office (Scotland), and ME Research UK. CS is the honorary medical adviser to the ME Association. JW was on the UK ME/CFS Research Collaborative Patient Advisory Group and received travel expenses for participation in board meetings. NM has authored an online e-learning module on ME/CFS and has received consultancy fees from the Learn about ME Project and Ono Pharmaceuticals as well as an honorarium from the GW4 ME/CFS Carers Project but has no direct or financial conflict of interest to declare in relation to this research. SC is CEO of Action for ME; co-chair of the World ME Alliance; and Chair, Future Ambitions Board, B&amp;NES. SL is head of advocacy and communications of the World ME Alliance. SMcG was formerly involved in the UK CFS/ME Research Collaborative Patient Advisory Group. Funding StatementDecodeME was funded by the National Institute for Health and Care Research (NIHR) and Medical Research Council (MRC), grant number MC_PC_20005. This work has made use of the resources provided by the Edinburgh Compute and Data Facility (ECDF) (http://www.ecdf.ed.ac.uk/) funded by MC_PC_MR/X013677/1. The study was also supported by the Medical Research Council University Unit award to the MRC Human Genetics Unit, University of Edinburgh, grant number MC_UU_00007/10 (SK, VV) and MC_UU_00007/15 (OA, JCW). This work was supported by a grant for PhD-level research to GLS from ME Research UK (SCIO charity number SCO36942). ADB would like to acknowledge funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z) and the Edinburgh Clinical Academic Track (ECAT) programme (https://wellcome.org/). HMO received support from the Research Council of Finland (353812). Genes &amp; Health is core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017, MR/X009777/1, MR/X009920/1), the Higher Education Funding Council for England Catalyst Fund, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). We acknowledge the support of the National Institute for Health and Care Research Barts Biomedical Research Centre (NIHR203330), which is a delivery partnership of Barts Health NHS Trust, Queen Mary University of London, St Georges University Hospitals NHS Foundation Trust and St Georges University of London. Genes &amp; Health is funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry Consortium of AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp &amp; Dohme LLC, Novo Nordisk A/S, Pfizer Inc, and Takeda Development Centre Americas Inc. The work of the Estonian Genome Center, University of Tartu was funded by the European Union through Horizon Europe research and innovation programs under grants no. 894987, 101137201 and 101137154, and Estonian Research Council Grant PRG1291. HMO and RS received support from NIH (R01AI170850). Cindy G. Boer and Sirine Saafi are funded by a ZonMW grant. The eQTL data used for the analyses described in this manuscript were obtained from the GTEx Portal on 05/23/25. The MRC and NIHR facilitated discussions between scientists and people with ME/CFS before we submitted our funding application but played no role in the design of the study, the collection, analysis, and interpretation of data, and the writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:North West Liverpool Central Research Ethics Committee gave a favourable opinion of the DecodeME study (21/NW/0169).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes</style></abstract></record></records></xml>